At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Not Yet Opened 02-04 16:00:00 EST
1.76
-0.34
-16.19%
盘后1.79
+0.03+1.70%
19:58 EST
High2.09Low1.72Vol110.73K
Open2.04D1 Closing2.10Amplitude17.62%
Mkt Cap2.64MTradable Cap2.20MTotal Shares1.50M
T/O214.67KT/O Rate8.87%Tradable Shares1.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes
Reuters  ·  05:17
Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes
Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt
Reuters  ·  05:17
Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt
Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation
TIPRANKS  ·  02-03 21:15
Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation
Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien
Reuters  ·  02-03 21:01
Clearmind Medicine erzielt Durchbruch mit MEAI in US-Gesetz für innovative Veteranen-Therapien
Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial
TIPRANKS  ·  01-15
Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial
BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months
Reuters  ·  01-14
BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months
Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months
THOMSON REUTERS  ·  01-14
Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months
Clearmind Medicine Completes Second Cohort Treatment in Phase I/IIa Trial for Alcohol Use Disorder Drug
Reuters  ·  01-14
Clearmind Medicine Completes Second Cohort Treatment in Phase I/IIa Trial for Alcohol Use Disorder Drug
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
GlobeNewswire  ·  01-14
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule
MT Newswires Live  ·  2025-12-31
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule
Clearmind Medicine Regains Compliance With Nasdaq Minimum Bid Price Requirement
THOMSON REUTERS  ·  2025-12-31
Clearmind Medicine Regains Compliance With Nasdaq Minimum Bid Price Requirement
Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial
Reuters  ·  2025-12-29
Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial
Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Reuters  ·  2025-12-24
Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Completes Second Cohort Enrollment in Phase I/IIa Trial for Alcohol Use Disorder Drug
Reuters  ·  2025-12-16
Clearmind Medicine Completes Second Cohort Enrollment in Phase I/IIa Trial for Alcohol Use Disorder Drug
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
GlobeNewswire  ·  2025-12-16
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny
Reuters  ·  2025-12-12
Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny
Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
THOMSON REUTERS  ·  2025-12-12
Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Clearmind Medicine Announces 1-for-40 Reverse Stock Split
Reuters  ·  2025-12-11
Clearmind Medicine Announces 1-for-40 Reverse Stock Split
Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
Reuters  ·  2025-12-06
Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing
Reuters  ·  2025-12-03
BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--